Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of guselkumab in active psoriatic arthritis
2014-003697-17Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guselkumab in psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: ACR20 response at week 24. Started Mar 2015; status: completed.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2014-003697-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003697-17.